Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 2Phase 2 1

Status

Terminated 6Completed 6Active not recruiting 3

Sponsor Class

INDUSTRY 5NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 5Other hematologic neoplasm 1Other 1Gastrointestinal 1

Conditions

Multiple Myeloma 4Purpura 1Nausea 1Macroglossia 1Lymphadenopathy 1Immunoglobulin Light-chain Amyloidosis 1Hepatomegaly 1Hematologic Neoplasms 1Gastrointestinal Hemorrhage 1Diarrhea 1Constipation 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Has results × isatuximab × Clear all
NCT03275285 2026-02-09

IKEMA

Sanofi

Phase 3 Completed
302 enrolled 38 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT03499808 2025-09-09

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

SWOG Cancer Research Network

Phase 2 Completed
43 enrolled 23 charts
GastrointestinalOtherPlasma cell

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

NCT02990338 2025-01-17

ICARIA-MM

Sanofi

Phase 3 Completed
307 enrolled 32 charts 1 FDA
Plasma cell

Multiple Myeloma

NCT01084252 2024-11-01

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Sanofi

Phase 1/2 Completed
351 enrolled 56 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT03194867 2024-06-14

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Sanofi

Phase 1/2 Completed
109 enrolled 27 charts
Plasma cell

Multiple Myeloma

NCT02812706 2024-04-01

Islands

Sanofi

Phase 1/2 Completed
36 enrolled 26 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡